rs1784931 — SORL1 SORL1 intron 39 variant

Intronic variant in the sortilin-related receptor that tags a 3′ haplotype block linked to reduced SORL1 brain expression; the A allele is associated with lower receptor levels and modestly increased Alzheimer's disease risk

See your personal result for SORL1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SORL1 — The APP Traffic Controller That Keeps Alzheimer's at Bay

Every neuron in your brain constantly recycles its membrane proteins through a network of intracellular sorting stations called endosomes. One of the most important proteins cycling through this network is APP — amyloid precursor protein — the molecule whose misprocessing produces the sticky amyloid-beta plaques that define Alzheimer's disease. The sorting receptor that decides which fate APP meets is encoded by SORL1 (sortilin-related receptor 111 sortilin-related receptor 1
Also known as SORLA or LR11; a 2,214-amino-acid transmembrane receptor expressed at highest levels in neurons). When SORL1 is present and functional, it binds APP in early endosomes and hands it off to the retromer complex for retrograde transport back to the trans-Golgi network — diverting it away from the late-endosomal compartments where β-secretase and γ-secretase cleave APP into amyloid-beta fragments. When SORL1 levels fall, APP lingers in late endosomes, amyloid-beta production rises, and the neuronal housekeeping system begins to fail.

rs1784931 is an intronic variant in the 3′ region of SORL1 (intron 39, c.5323-507C>A, chromosome 11 position 121,612,229 GRCh38). It does not alter the protein but tags a haplotype block that influences how efficiently the gene is expressed in brain tissue. The A allele marks a risk haplotype associated with reduced SORL1 mRNA and protein in the brain, while the C allele tags a more protective configuration associated with higher receptor levels.

The Mechanism

SORL1 intersects with APP at multiple trafficking nodes. In the early endosome, SORL1 physically binds APP through both its extracellular LDLR class-A domain and its intracellular FANSHY motif22 FANSHY motif
the cytoplasmic tail sequence that engages the retromer VPS35 subunit. This dual grip allows SORL1 to transfer APP to the retromer complex, which routes it retrogradely to the trans-Golgi network. The net effect is that APP bypasses the late-endosomal compartment where BACE1 (β-secretase) and γ-secretase are concentrated. When SORL1 is knocked out in human iPSC-derived neurons, APP accumulates in enlarged early endosomes33 APP accumulates in enlarged early endosomes
Knupp et al. 2022 showed significantly increased early-endosomal APP localization, enlarged Rab5+ and Rab11+ compartments, and impaired surface recycling of multiple cargo proteins, APP trafficking is disrupted, and amyloid-beta production increases. SORL1 also routes Aβ peptides already formed toward lysosomes for degradation via its VPS10 domain — a second line of defense that is also lost when receptor levels fall.

The rs1784931 A allele tags a 3′ haplotype block (in linkage disequilibrium with rs1699102, rs3824968, rs2282649, and rs1010159) that was shown to alter codon usage in SORL1 transcripts, reducing translational efficiency44 reducing translational efficiency
Caglayan et al. 2012 showed the risk haplotype changes frequent-to-rare codon usage in minor transcripts, impairing ribosomal elongation rate. Carriers of the risk haplotype at the 3′ cluster show reduced SORL1 protein in frontal cortex autopsy tissue from Alzheimer's disease brains. Separately, A-allele homozygotes at rs1784931 showed significantly reduced prefrontal SORL1 mRNA compared to CC homozygotes in post-mortem brain data, with the effect driven by Caucasian samples.

The Evidence

The genetic association between SORL1 common variants and late-onset Alzheimer's disease was first established by Rogaeva et al. in a landmark Nature Genetics paper55 Rogaeva et al. in a landmark Nature Genetics paper
Study of 19 SNPs in four ethnicities: Caucasian (Mayo Clinic, 1,400 cases/controls), Caribbean-Hispanic, Israeli-Arab, and African-American; two haplotype clusters independently replicated across populations. They identified two distinct LD blocks: a 5′ cluster (SNPs 8-10) and a 3′ cluster (SNPs 22-25). The risk haplotype for the 3′ cluster showed odds ratios for AD of approximately 1.3–1.5 across multiple populations, with consistent directionality of association. rs1784931 falls within the same 3′ linkage disequilibrium block as this cluster.

The association was replicated in a 2007 multiethnic community cohort66 2007 multiethnic community cohort
Lee et al. 2007 — 296 AD cases, 428 controls, African-American, Caribbean-Hispanic, and non-Hispanic white participants from northern Manhattan and subsequently confirmed by a large meta-analysis of 12,464 AD cases and 17,929 controls77 meta-analysis of 12,464 AD cases and 17,929 controls
Reitz et al. 2011 — both the 5′ CGC haplotype (SNPs 8-10) and 3′ SNPs (19, 23-25) remained significant after Bonferroni correction across white and Asian populations. The same 3′ haplotype variants were linked to multiple AD endophenotypes: white matter hyperintensities, hippocampal atrophy on MRI, and cerebrospinal fluid amyloid-beta levels.

For rs1784931 specifically, the C;C genotype is associated with approximately 0.83× the population risk of Alzheimer's disease (a ~17% relative risk reduction), while A;A homozygotes show modestly elevated risk. The effect is modest in isolation — SORL1 common variants are secondary risk factors compared to APOE ε4, but the mechanism is well-validated and the biology directly connects reduced SORL1 expression to amyloid-beta accumulation.

Practical Actions

rs1784931 is a common intronic variant, not a rare pathogenic mutation. Carriers of the A allele do not have a SORL1 deficiency syndrome — they simply sit on a haplotype associated with somewhat less efficient SORL1 expression in brain tissue. The modest effect on AD risk (OR ~1.2-1.3 per A allele copy) means this variant is informative for long-range risk awareness rather than urgent clinical action.

SORL1 expression is upregulated by brain-derived neurotrophic factor (BDNF) and by retinoic acid88 retinoic acid
BDNF and retinoic acid signaling promote SORL1 transcription in neurons; A-allele carriers show blunted BDNF-induced SORL1 upregulation in some studies. Regular aerobic exercise is the best-validated intervention for raising brain BDNF levels, and the SORL1-BDNF connection makes this particularly relevant for carriers of the A allele. Monitoring cognitive function over time — through validated tools such as the MoCA or periodic neuropsychological assessment — is prudent for A;A homozygotes with additional risk factors (APOE ε4, family history, cardiovascular risk).

Interactions

The most clinically important interaction is with APOE ε4 (rs429358 / rs7412). SORL1 mediates neuronal cholesterol uptake by acting as a receptor for apolipoprotein E, with preferential binding to the APOE ε4 isoform. Individuals who carry both an A allele at rs1784931 and APOE ε4 face compounded amyloid-beta accumulation risk: reduced SORL1 levels impair APP routing while APOE ε4 independently amplifies amyloidogenic processing and impairs Aβ clearance. The combination is additive or possibly supra-additive.

The retromer pathway also connects SORL1 to VPS35 variants (rs6733839, VPS35 D620N): retromer dysfunction from either SORL1 deficiency or VPS35 loss produces similar endosomal trafficking failures. Carriers of A alleles at rs1784931 with concurrent retromer pathway variants may warrant earlier cognitive monitoring.

Genotype Interpretations

What each possible genotype means for this variant.

CC Protective SORL1 Expression Beneficial

Two copies of the protective allele — highest SORL1 expression and lowest AD risk from this locus

You carry two C alleles at rs1784931, the genotype associated with the highest SORL1 expression in brain tissue among the three possible genotypes at this locus. The C allele tags a haplotype configuration that supports more efficient SORL1 translation in neurons, providing optimal APP trafficking away from amyloidogenic processing pathways. Post-mortem brain studies show CC homozygotes have higher prefrontal SORL1 mRNA than A-allele carriers, and SNPedia cites this genotype as associated with approximately 0.83× the population risk for Alzheimer's disease — a modest but consistent protective signal. About 36% of the global population and roughly 19% of Europeans carry this genotype.

AC Intermediate SORL1 Expression Intermediate

One A allele and one protective C allele — mildly reduced SORL1 expression and slightly elevated AD risk

SORL1 expression follows an additive pattern across rs1784931 genotypes: CC carriers show the highest brain levels, AA carriers the lowest, and AC heterozygotes fall in between. One copy of the A allele shifts codon usage in a minority of SORL1 transcripts toward rarer codons, mildly reducing translational efficiency without completely impairing receptor production. The net result is slightly less SORL1 protein available for APP trafficking in neurons — a minor but detectable reduction in the neuronal defense against amyloidogenic processing.

The meta-analytic evidence supports an additive model for this variant: each A allele copy adds approximately equal increments of AD risk, so AC carriers sit roughly halfway between CC and AA in terms of effect on SORL1 expression and lifetime risk.

AA Reduced SORL1 Expression High Risk

Two copies of the risk allele — reduced SORL1 brain expression and modestly elevated Alzheimer's risk

The rs1784931 A allele tags a 3′ SORL1 haplotype (in LD with rs1699102, rs3824968, rs2282649, and rs1010159) that was functionally linked to reduced translational efficiency of SORL1 transcripts in Alzheimer's disease brain tissue. A-allele homozygotes show the lowest prefrontal SORL1 mRNA across genotype groups in Caucasian post-mortem datasets.

The downstream consequence is mechanistically straightforward: less SORL1 protein means less retromer-mediated APP recycling out of early endosomes. APP that is not retrieved by SORL1 is exposed to BACE1 and γ-secretase in the late-endosomal compartment, increasing Aβ40 and Aβ42 production. The effect size is moderate — this is not a rare pathogenic mutation but a common regulatory variant that shifts the probability distribution of amyloid accumulation over decades.

Additional risk factors amplify this variant's impact. APOE ε4 carriers who also carry A/A at rs1784931 face both reduced SORL1-mediated APP diversion and impaired Aβ clearance from the APOE ε4 pathway — a compounded vulnerability. Family history, cardiovascular risk, and sleep quality all interact with amyloid accumulation rates independently of genetics.